Does semaglutide affect your resting heart rate?

The misconception worth clearing up first

A common worry, and a question our prescribers hear most weeks, is that a faster pulse on semaglutide means the medicine is putting strain on the heart. It is understandable, and if you have found yourself wondering whether Wegovy makes your heart beat faster and what that actually means, you are not alone. The reality is more reassuring. The modest heart rate increase seen in Wegovy trials is a pharmacological effect of GLP-1 receptor activation, not a marker of cardiac stress. It is separate from the question of whether semaglutide is good for the heart overall, which is a different and rather more positive story.

GLP-1 receptors sit in several tissues, including the sinoatrial node that sets the heart's rhythm. When semaglutide activates those receptors, the node fires slightly faster. That is the mechanism. It does not mean the heart is working harder in a harmful sense, and it is not the same physiological process as the racing pulse you get from anxiety or exercise. Understanding how semaglutide affects heart rate at a mechanistic level can make this side effect feel far less alarming when you encounter it. The NHS patient information for semaglutide lists increased heart rate among the known side effects to be aware of, placing it in context alongside the medicine's overall profile.

How big is the resting heart rate change, and does it settle?

In the STEP 1 trial (68 weeks, semaglutide 2.4mg versus placebo) the average increase in resting heart rate was modest: in the region of two to five beats per minute. Individual variation matters. Some participants noticed little change; a smaller number saw more pronounced rises, particularly around dose increases. The increase tends to be most noticeable in the early weeks, and for a significant proportion of people it stabilises or partially reverses as weight loss progresses.

Here is why that matters: excess body weight independently raises resting heart rate. As weight comes down, the cardiovascular system faces less demand. Over a treatment course of a year or more, the net effect on resting pulse for many patients is neutral or even a reduction compared to baseline. The STEP 1 paper in the New England Journal of Medicine provides the granular data on cardiovascular parameters across the trial period for anyone who wants to read the primary evidence.

Wegovy also holds a UK authorisation for reducing the risk of major cardiovascular events in eligible adults with established cardiovascular disease, a reassurance that the overall cardiac picture is not defined by the heart rate finding alone. If you want a fuller look at how semaglutide interacts with heart health more broadly, that context is covered separately.

Who should pay closer attention to this effect?

For the majority of people starting Wegovy for weight management, a small pulse increase needs monitoring but is not a reason to avoid treatment. There are groups where closer attention is warranted. Anyone with a pre-existing arrhythmia, particularly a tachycardia such as atrial fibrillation or SVT, should tell their prescriber before starting, not because semaglutide is contraindicated in most of these cases, but because the baseline context changes the risk calculation. The same applies to people on rate-controlling medicines like beta-blockers or calcium-channel blockers, where a prescriber may want to track pulse more carefully across dose increases.

The practical advice from NHS England's guidance on weight-management injections is to keep your wider clinical team informed, your GP included. This is why semaglutide is a prescription-only medicine rather than something available over the counter: the individual assessment matters. If you are on current treatment elsewhere and considering a switch, what Wegovy involves is worth reading before your consultation.

Severe palpitations, chest pain, breathlessness or a heart rate that feels alarmingly fast at rest are different. Those are signs to seek same-day medical advice, not to wait for your next prescription review. Most people experience nothing close to that; but the distinction between a minor pharmacological blip and a symptom needing urgent attention is one worth knowing.

Monitoring pulse during treatment: what is practical

You do not need a medical-grade device. A consumer fitness tracker or the pulse function on most smartphones gives a reasonable resting measurement taken first thing in the morning before getting up. Note your baseline before you start treatment. Check it once or twice a week in the first month and around each dose step. A rise of a few beats per minute with no accompanying symptoms is expected and, based on the trial data, generally self-limiting.

If your reading is consistently 20 or more beats per minute above your pre-treatment baseline, or if you feel symptomatic, that is the time to contact your prescriber rather than self-managing. At nume, our aftercare team is available seven days a week for exactly this kind of question between formal prescription reviews. For background on how the Wegovy and heart rate picture fits into the broader cardiovascular evidence, there is more detail on that page. Curious about the price context for private treatment? What Wegovy costs in the UK is covered honestly, without glossing over what legitimate treatment includes.